Abstract |
Tumor cells increase their glucose consumption through aerobic glycolysis to manufacture the necessary biomass required for proliferation, commonly known as the Warburg effect. Accumulating evidences suggest that microRNAs ( miRNAs) interact with their target genes and contribute to metabolic reprogramming in cancer cells. By integrating high-throughput screening data and the existing miRNA expression datasets, we explored the roles of candidate glycometabolism-regulating miRNAs in gastric cancer (GC). Subsequent investigation of the characterized miRNAs indicated that miR-129-5p inhibits glucose metabolism in GC cells. miRNA-129-5p directly targets the 3'-UTR of SLC2A3, thereby suppressing glucose consumption, lactate production, cellular ATP levels, and glucose uptake of GC cells. In addition, the PI3K-Akt and MAPK signaling pathways are involved in the effects of the miR-129-5p/SLC2A3 axis, regulating GC glucose metabolism and growth. These results reveal a novel role of the miR-129-5p/SLC2A3 axis in reprogramming the glycometabolism process in GC cells and indicate a potential therapeutic target for the treatment of this disease.
|
Authors | Di Chen, Hui Wang, Jie Chen, Zhe Li, Shengli Li, Zhixiang Hu, Shenglin Huang, Yingjun Zhao, Xianghuo He |
Journal | Frontiers in pharmacology
(Front Pharmacol)
Vol. 9
Pg. 502
( 2018)
ISSN: 1663-9812 [Print] Switzerland |
PMID | 29867504
(Publication Type: Journal Article)
|